|
[1]
|
Kyle, R.A., Therneau, T.M., Rajkumar, S.V., et al. (2006) Prevalence of Monoclonal Gammopathy of Undetermined Significance. The New England Journal of Medicine, 354, 1362-1369. [Google Scholar] [CrossRef]
|
|
[2]
|
梁丹, 黄湘华, 任贵生, 等. 多发性骨髓瘤伴肾脏病变患者的临床病理特征和预后[J]. 肾脏病与透析肾移植杂志, 2016, 25(5): 401-408.
|
|
[3]
|
Heher, E.C., Rennke, H.G., Laubach, J.P., et al. (2013) Kidney Disease and Multiple Myeloma. Clinical Journal of the American Society of Nephrology: CJASN, 8, 2007-2017. [Google Scholar] [CrossRef]
|
|
[4]
|
Kumar, S.K., Callander, N.S., Hillengass, J., et al. (2019) NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 17, 1154-1165. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef]
|
|
[6]
|
Nanagopal, L., Ye, J.C., Ventimiglia, M., et al. (2014) Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed by Autologous Stem Cell Transplant. Blood, 124, 5904-5904. [Google Scholar] [CrossRef]
|
|
[7]
|
Kndsen, L.M., Hjorth, M. and Hippe, E. (2000) Renal Failure in Multiple Myeloma: Reversibility and Impact on the Prognosis. Nordic Myeloma Study Group. European Journal of Haematology, 65, 175-181. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Rehtina, I.G., Mendeleeva, L.P. and Biryukova, L.S. (2016) Dialysis-Dependent Renal Failure in Patients with Multiple Myeloma: Reversibility Factors. Terapevticheskii arkhiv, 87, 72-76. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Chen, X., Luo, X., Zu, Y., et al. (2020) Severe Renal Impairment as an Adverse Prognostic Factor for Survival in Newly Diagnosed Multiple Myeloma Patients. Journal of Clinical Laboratory Analysis, 34, e23416. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Howlader, N., Noone, A.M., Krapcho, M., et al. (2013) Seer Cancer Statistics Review, 1975-2012. National Cancer Institute.
|
|
[11]
|
Ozsan, G.H. and Dispenzieri, A. (2011) Serum Free Light Chain Analysis in Multiple Myeloma and Plasma Cell Dyscrasias. Expert Review of Clinical Immunology, 7, 65-73. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
International Myeloma Working Group (2003) Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Nakano, T., Miyazaki, S., Takahashi, H., et al. (2006) Immunochemical Quantification of Free Immunoglobulin Light Chains from an Analytical Perspective. Clinical Chemistry and Laboratory Medicine, 44, 522-532. [Google Scholar] [CrossRef]
|
|
[14]
|
周晓, 翟勇平, 梅建刚, 等. 本周氏蛋白催化作用与多发性骨髓瘤患者肾损伤的关系[J]. 中国实验血液学杂志, 2012, 20(2): 339-343.
|
|
[15]
|
Favà, A., Fulladosa, X., Montero, N., et al. (2018) Treatment of Multiple Myeloma with Renal Involvement: The Nephrologist’s View. Clinical Kidney Journal, 11, 777-785. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Li, M., Hering-Smith, K.S., Simon, E.E., et al. (2008) Myeloma Light Chains Induce Epithelial-Mesenchymal Transition in Human Renal Proximal Tubule Epithelial Cells. Nephrology, Dialysis, Transplantation, 23, 860-870. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Arimura, A., Li, M. and Batuman, V. (2006) Potential Protective Action of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP38) on In Vitro and In Vivo Models of Myeloma Kidney Injury. Blood, 107, 661-668. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Ying, W.Z., Wang, P.X., Aaron, K.J., et al. (2011) Immunoglobulin Light Chains Activate Nuclear Factor-κB in Renal Epithelial Cells through a Src-Dependent Mechanism. Blood, 117, 1301-1307. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Chen, X.D., Luo, X.F., Zu, Y.P., et al. (2019) Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma. Journal of Experimental Hematology, 27, 1862-1868. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Yadav, P., Cook, M. and Cockwell, P. (2016) Current Trends of Renal Impairment in Multiple Myeloma. Kidney Diseases (Basel, Switzerland), 1, 241-257. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Yadav, P., Cockwell, P., Cook, M., et al. (2018) Serum Free Light Chain Levels and Renal Function at Diagnosis in Patients with Multiple Myeloma. BMC Nephrology, 19, 178. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Laterza, O.F., Price, C.P. and Scott, M.G. (2002) Cystatin C: An Improved Estimator of Glomerular Filtration Rate? Clinical Chemistry, 48, 699-707. [Google Scholar] [CrossRef]
|
|
[23]
|
杨敏. 多发性骨髓瘤患者血清Cys-C、Urea、Scr及β2-MG水平检测及其临床意义[J]. 标记免疫分析与临床, 2019, 26(3): 506-510.
|
|
[24]
|
Grubb, A., Horio, M., Hansson, L.O., et al. (2014) Generation of a New Cystatin C-Based Estimating Equation for Glomerular Filtration Rate by Use of 7 Assays Standardized to the International Calibrator. Clinical Chemistry, 60, 974-986. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
许光银, 乔彩霞, 王志玉. 多项生物学标志物联合检测在重症患者合并急性肾损伤早期诊断中的价值[J]. 中华肾脏病杂志, 2014, 30(3): 166-171.
|
|
[26]
|
De Vos, J., Thykjaer, T., Tarte, K., et al. (2002) Comparison of Gene Expression Profiling between Malignant and Normal Plasma Cells with Oligonucleotide Arrays. Oncogene, 21, 6848-6857. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Terpos, E., Katodritou, E., Tsiftsakis, E., et al. (2009) Cystatin-C Is an Independent Prognostic Factor for Survival in Multiple Myeloma and Is Reduced by Bortezomib Administration. Haematologica, 94, 372-379. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Dimopoulos, M.A., Kastritis, E., Michalis, E., et al. (2012) The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients’ Renal Function. Annals of Oncology, 23, 722-729. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Shlipak, M.G., Matsushita, K., Ärnlöv, J., Inker, et al. (2013) Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. The New England Journal of Medicine, 369, 932-943. [Google Scholar] [CrossRef]
|
|
[30]
|
Roy, P., Sarkar, U.A. and Basak, S. (2018) The NF-κB Activating Pathways in Multiple Myeloma. Biomedicines, 6, 59. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Mori, K. and Nakao, K. (2007) Neutrophil Gelatinase-Associated Lipocalin as the Real-Time Indicator of Active Kidney Damage. Kidney International, 71, 967-970. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Nejat, M., Pickering, J.W., Devarajan, P., et al. (2012) Some Biomarkers of Acute Kidney Injury Are Increased in Pre-Renal Acute Injury. Kidney International, 81, 1254-1262. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Nguen, M.T. and Devarajan, P. (2008) Biomarkers for the Early Detection of Acute Kidney Injury. Pediatric Nephrology (Berlin, Germany), 23, 2151-2157. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Sundaram, M., Sivaprasadarao, A., DeSousa, M.M., et al. (1998) The Transfer of Retinol from Serum Retinol-Binding Protein to Cellular Retinol-Binding Protein Is Mediated by a Membrane Receptor. The Journal of Biological Chemistry, 273, 3336-3342. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Naylor, H.M. and Newcomer, M.E. (1999) The Structure of Human Retinol-Binding Protein (RBP) with Its Carrier Protein Transthyretin Reveals an Interaction with the Carboxy Terminus of RBP. Biochemistry, 38, 2647-2653. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Bernard, A., Viau, C., Ouled, A., et al. (1987) Competition between Low- and High-Molecular-Weight Proteins for Renal Tubular Uptake. Nephron, 45, 115-118. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Corso, A., Serricchio, G., Zappasodi, P., et al. (1999) Assessment of Renal Function in Patients with Multiple Myeloma: The Role of Urinary Proteins. Annals of Hematology, 78, 371-375. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Gavrilov, V., Yermiahu, T. and Gorodischer, R. (2006) Renal Pathology and Retinol Status in Multiple Myeloma Patients. Kidney International, 69, 173-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
刘荣荣, 彭洪菊. 多发性骨髓瘤患者血清β2-微球蛋白、TNF-α、CRP及IL-6水平检测的临床价值[J]. 航空航天医学杂志, 2018, 29(1): 48-49.
|
|
[40]
|
Kyle, R.A., Gertz, M.A., Witzig, T.E., et al. (2003) Review of 1027 Patients with Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 78, 21-33. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
赵霞, 许庆, 丁慧芳, 等. DC-CIK联合化疗对多发性骨髓瘤患者细胞免疫功能的影响[J]. 中国免疫学杂志, 2015, 31(4): 490-496.
|
|
[42]
|
Madalena, L., Facio, M.L., Angerosa, M., et al. (2007) Urinary Excretion of Low Molecular Weight Proteins in Patients with Pure Monoclonal Light Chain Proteinuria. Journal of Nephrology, 20, 683-688.
|
|
[43]
|
Kim, J.E., Yoo, C., Lee, D.H., et al. (2010) Serum Albumin Level Is a Significant Prognostic Factor Reflecting Disease Severity in Symptomatic Multiple Myeloma. Annals of Hematology, 89, 391-397. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
van Timmeren, M.M., van den Heuvel, M.C., Bailly, V., et al. (2007) Tubular Kidney Injury Molecule-1 (KIM-1) in Human Renal Disease. The Journal of Pathology, 212, 209-217. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Gobe, G.C., Coombes, J.S., Fassett, R.G., et al. (2015) Biomarkers of Drug-Induced Acute Kidney Injury in the Adult. Expert Opinion on Drug Metabolism & Toxicology, 11, 1683-1694. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Vaidya, V.S., Ozer, J.S., Dieterle, F., et al. (2010) Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Preclinical Biomarker Qualification Studies. Nature Biotechnology, 28, 478-485. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Chiusolo, A., Defazio, R., Zanetti, E., et al. (2010) Kidney Injury Molecule-1 Expression in Rat Proximal Tubule after Treatment with Segment-Specific Nephrotoxicants: A Tool for Early Screening of Potential Kidney Toxicity. Toxicologic Pathology, 38, 338-345. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Zdzisińska, B., Walter-Croneck, A. and Kandefer-Szerszeń, M. (2008) Matrix Metalloproteinases-1 and -2, and Tissue Inhibitor of Metalloproteinase-2 Production Is Abnormal in Bone Marrow Stromal Cells of Multiple Myeloma Patients. Leukemia Research, 32, 1763-1769. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Ronco, C. (2016) Acute Kidney Injury: From Clinical to Molecular Diagnosis. Critical Care (London, England), 20, 201. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Yang, Q.H., Liu, D.W., Long, Y., et al. (2009) Acute Renal Failure during Sepsis: Potential Role of Cell Cycle Regulation. The Journal of Infection, 58, 459-464. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Seo, D.W., Li, H., Qu, C.K., et al. (2006) Shp-1 Mediates the Antiproliferative Activity of Tissue Inhibitor of Metalloproteinase-2 in Human Microvascular Endothelial Cells. The Journal of Biological Chemistry, 281, 3711-3721. [Google Scholar] [CrossRef]
|
|
[52]
|
Zuo, S., Liu, C., Wang, J., et al. (2012) IGFBP-rP1 Induces p21 Expression through a p53-Independent Pathway, Leading to Cellular Senescence of MCF-7 Breast Cancer Cells. Journal of Cancer Research and Clinical Oncology, 138, 1045-1055. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Wang, Z., Famulski, K., Lee, J., et al. (2014) TIMP2 and TIMP3 Have Divergent Roles in Early Renal Tubulointerstitial Injury. Kidney International, 85, 82-93. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Boonstra, J. and Post, J.A. (2004) Molecular Events Associated with Reactive Oxygen Species and Cell Cycle Progression in Mammalian Cells. Gene, 337, 1-13. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Rodier, F., Campisi, J. and Bhaumik, D. (2007) Two Faces of p53: Aging and Tumor Suppression. Nucleic Acids Research, 35, 7475-7484. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Stetler-Stevenson, W.G. (2008) Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities. Science Signaling, 1, re6. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Witzgall, R., Brown, D. and Schwarz, C. (1994) Localization of Proliferating Cell Nuclear Antigen, Vimentin, c-Fos, and Clusterin in the Postischemic Kidney. Evidence for a Heterogenous Genetic Response among Nephron Segments, and a Large Pool of Mitotically Active and Dedifferentiated Cells. The Journal of Clinical Investigation, 93, 2175-2188. [Google Scholar] [CrossRef]
|
|
[58]
|
Katz, N. and Ronco, C. (2016) Acute Kidney Stress—A Useful Term Based on Evolution in the Understanding of Acute Kidney Injury. Critical Care (London, England), 20, 23. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Emlet, D.R., Pastor-Soler, N., Marciszyn, A., et al. (2017) Insulin-Like Growth Factor Binding Protein 7 and Tissue Inhibitor of Metalloproteinases-2: Differential Expression and Secretion in Human Kidney Tubule Cells. American Journal of Physiology. Renal Physiology, 312, F284-F296. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Xia, Y. and Schneyer, A.L. (2009) The Biology of Activin: Recent Advances in Structure, Regulation and Function. The Journal of Endocrinology, 202, 1-12. [Google Scholar] [CrossRef]
|
|
[61]
|
Takei, Y., Takahashi, S., Nakasatomi, M., et al. (2019) Urinary Activin A Is a Novel Biomarker Reflecting Renal Inflammation and Tubular Damage in ANCA-Associated Vasculitis. PLoS ONE, 14, e0223703. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Iriuchishima, H., Maeshima, A., Takahashi, S., et al. (2019) Activin A: A Novel Urinary Biomarker of Renal Impairment in Multiple Myeloma. Bioscience Reports, 39, BSR20190206. [Google Scholar] [CrossRef]
|
|
[63]
|
Clark, A.D., Shetty, A. and Soutar, R. (1999) Renal Failure and Multiple Myeloma: Pathogenesis and Treatment of Renal Failure and Management of Underlying Myeloma. Blood Reviews, 13, 79-90. [Google Scholar] [CrossRef]
|
|
[64]
|
Cheng, J., Zhang, W., Zhao, Y., et al. (2021) Association of Serum Calcium Levels with Renal Impairment and All-Cause Death in Chinese Patients with Newly Diagnosed Multiple Myeloma: A Cross-Sectional, Longitudinal Study. Nutrition & Metabolism, 18, 19. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Hutchison, C.A., Batuman, V., Behrens, J., et al. (2011) The Pathogenesis and Diagnosis of Acute Kidney Injury in Multiple Myeloma. Nature Reviews. Nephrology, 8, 43-51. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Silvestris, F., Cafforio, P., Tucci, M., et al. (2002) Negative Regulation of Erythroblast Maturation by Fas-L(+)/TRAIL(+) Highly Malignant Plasma Cells: A Major Pathogenetic Mechanism of Anemia in Multiple Myeloma. Blood, 99, 1305-1313. [Google Scholar] [CrossRef]
|
|
[67]
|
Agarwal, J.R., Wang, Q., Tanno, T., et al. (2014) Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma. Molecular Cancer Therapeutics, 13, 1873-1881. [Google Scholar] [CrossRef]
|
|
[68]
|
Faquin, W.C., Schneider, T.J. and Goldberg, M.A. (1992) Effect of Inflammatory Cytokines on Hypoxia-Induced Erythropoietin Production. Blood, 79, 1987-1994. [Google Scholar] [CrossRef]
|
|
[69]
|
刘萌萌, 许洪志, 冯秀梅, 等. 多发性骨髓瘤肾损害危险因素及其可逆性预测指标的临床相关研究[J]. 中国实验血液学杂志, 2015, 23(3): 722-727.
|
|
[70]
|
Cohen, L.F., Balow, J.E., Magrath, I.T., et al. (1980) Acute Tumor Lysis Syndrome. A Review of 37 Patients with Burkitt’s Lymphoma. The American Journal of Medicine, 68, 486-491. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Kang, D.H., Nakagawa, T., Feng, L., et al. (2002) A Role for Uric Acid in the Progression of Renal Disease. Journal of the American Society of Nephrology: JASN, 13, 2888-2897. [Google Scholar] [CrossRef]
|
|
[72]
|
Sánhez-Lozada, L.G., Lanaspa, M.A., Cristóbal-García, M., et al. (2012) Uric Acid-Induced Endothelial Dysfunction Is Associated with Mitochondrial Alterations and Decreased Intracellular ATP Concentrations. Nephron. Experimental Nephrology, 121, e71-e78. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Ryu, E.S., Kim, M.J., Shin, H.S., et al. (2013) Uric Acid-Induced Phenotypic Transition of Renal Tubular Cells as a Novel Mechanism of Chronic Kidney Disease. American Journal of Physiology. Renal Physiology, 304, F471-F480. [Google Scholar] [CrossRef] [PubMed]
|